Robert Torray
Torray Fund
Torray Fund Royalty PharmaPlc stake
total: 71
Torray Fund RPRX trades
- Total transactions:
- 6
- New positions:
- 1
- Added:
- 2
- Reduced:
- 3
- Held since:
- 2023 Q2
- Held for:
- 13 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Torray Fund holds 300,000 Royalty PharmaPlc (RPRX) shares with a market value of roughly $16.73M accounting for 4.71% of the overall portfolio. To date, the estimated cost basis is nearly $30.23 for "buy" trades and estimated average "sell" price is $41.51. Torray Fund first purchased RPRX in 2023 Q2, initially acquiring 270,835 shares. Since the initial investment in Royalty PharmaPlc (RPRX), Torray Fund has made 5 more transactions.
When did Torray Fund buy Royalty PharmaPlc (RPRX)?
Torray Fund first invested in Royalty PharmaPlc (RPRX) in 2023 Q2 at the reported quarter-end price of $30.74 per share.
What's the cost basis of Torray Fund's RPRX stake?
The estimated cost basis for Royalty PharmaPlc (RPRX) stake is around $30.23 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $30.23
- Weighted AVG sell price:
- $41.50
Torray Fund's historical trades in Royalty PharmaPlc
6 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
4.71%
|
300,000
|
$55.76
|
$16,728,000
|
-14.29% (-50,000)
|
-0.82%
|
|
2026 Q1
|
4.74%
|
350,000
|
$46.21
|
$16,173,500
|
-11.90% (-47,290)
|
-0.61%
|
|
2025 Q2
|
3.94%
|
397,290
|
$32.88
|
$13,062,895
|
-21.44% (-108,435)
|
-1.03%
|
|
2024 Q3
|
4.13%
|
505,725
|
$29.03
|
$14,681,197
|
+33.28% (+126,275)
|
+1.03%
|
|
2024 Q1
|
3.34%
|
379,450
|
$30.34
|
$11,512,513
|
+40.10% (+108,615)
|
+0.96%
|
|
2023 Q2
|
2.65%
|
270,835
|
$30.74
|
$8,325,468
|
new
|
+2.65%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.